This products are only offered after regulatory clearance in various jurisdictions
Our main focus is to produce, autologous and allogeneic, hypoimmunogenic hair-follicles for hair-loss treatment in clinics and transplantation into the human scalp, whereas both cell lines from autologous and allogeneic sources will be (gene-) edited in order to prevent rejection of the transplant. Our approach is patent protected.
The respective - IPS Cell and Dermal Papillae Cell - merger sequences are described in FIG.1-4 (simplified) below:
FIG. 5 above: microscopic picture of an early HAIROID™️ prototype (methodical picture overview of our in-vitro produced hair follicles, finalized 7. January 2018)
FIG. 6 above: illustrates immunological responses that activate and inhibit allogenic transplant rejection